Skip to main content

Recent Patents Related to Phosphorylation Signaling Pathway on Cancer

Buy Article:

$113.00 plus tax (Refund Policy)

Abstract:

Phosphorylation and dephosphorylation play an important role in the regulation of growth factor and cytokine signal transduction to modulate cell proliferation, differentiation, survival, and apoptosis. In some cellular systems, the information suggests that EGFR, somatostatin receptors, SHP-1, Akt and PI3K can regulate carcinogenesis implied process through regulated the activity of NF-κB. Current patents related to signaling pathway that includes somatostatin receptors, phosphotyrosine phosphatases, tyrosine kinases, AKT/PKB and PI3K are focusing in diagnosis, prognosis and treatment. Many recent patented techniques include inhibition, antagonism or alternative therapeutic methods. Furthermore, it is necessary to deepen understanding of the molecular mechanisms involved in cancer to develop other alternative therapies focusing not only on new inhibitors.





Keywords: DNA-PK, Akt; Duals PTP; EGF receptor; Non Receptor Classic PTP; PDGF receptor; Phosphotyrosine kinases; Receptor Classic PTP; SSTR2 / SHP-1; VEGF receptor; cancer; cleavable marker; diagnosis; mTorC1; phosphotyrosine phosphatases; retinal blindness; signaling pathway; treatment

Document Type: Research Article

DOI: https://doi.org/10.2174/187221511797636257

Publication date: 2011-12-01

More about this publication?
  • Recent Patents on DNA and Gene Sequences publishes review articles by experts on recent patents on DNA and gene sequences. A selection of important and recent patents in the field is also included in the journal. The journal is essential reading for all researchers involved in applied molecular biology.
  • Access Key
  • Free ContentFree content
  • Partial Free ContentPartial Free content
  • New ContentNew content
  • Open Access ContentOpen access content
  • Partial Open Access ContentPartial Open access content
  • Subscribed ContentSubscribed content
  • Partial Subscribed ContentPartial Subscribed content
  • Free Trial ContentFree trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more